inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged 18+ 3. negative hiv, hepatitis, and syphilis test results 4. a negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay 5. a negative test result for covid-2019 by pcr at screening visit 6. no covid-2019 in the medical history 7. no contact with covid-2019 persons within at least 14 days before the enrollment (according to trial subjects) 8. consent to use effective contraception methods during the trial 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. negative drugs or psychostimulants urine test at the screening visit 11. negative alcohol test at the screening visit 12. no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 13. no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged 18+ 3. negative hiv, hepatitis, and syphilis test results 4. a negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay 5. a negative test result for covid-2019 by pcr at screening visit 6. no covid-2019 in the medical history 7. no contact with covid-2019 persons within at least 14 days before the enrollment (according to trial subjects) 8. consent to use effective contraception methods during the trial 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. negative drugs or psychostimulants urine test at the screening visit 11. negative alcohol test at the screening visit 12. no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 13. no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: written informed consent of a subject to participate in the trial males and females aged 18+ negative hiv, hepatitis, and syphilis test results a negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay a negative test result for covid-2019 by pcr at screening visit no covid-2019 in the medical history no contact with covid-2019 persons within at least 14 days before the enrollment (according to trial subjects) consent to use effective contraception methods during the trial negative urine pregnancy test at the screening visit (for child-bearing age women) negative drugs or psychostimulants urine test at the screening visit negative alcohol test at the screening visit no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: written informed consent of a subject to participate in the trial males and females aged 18+ negative hiv, hepatitis, and syphilis test results a negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay a negative test result for covid-2019 by pcr at screening visit no covid-2019 in the medical history no contact with covid-2019 persons within at least 14 days before the enrollment (according to trial subjects) consent to use effective contraception methods during the trial negative urine pregnancy test at the screening visit (for child-bearing age women) negative drugs or psychostimulants urine test at the screening visit negative alcohol test at the screening visit no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged 18+ 3. negative hiv, hepatitis, and syphilis test results 4. a negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay 5. a negative test result for covid-2019 by pcr at screening visit 6. no covid-2019 in the medical history 7. no contact with covid-2019 persons within at least 14 days before the enrollment (according to trial subjects) 8. consent to use effective contraception methods during the trial 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. negative drugs or psychostimulants urine test at the screening visit 11. negative alcohol test at the screening visit 12. no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 13. no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged 18+ 3. negative hiv, hepatitis, and syphilis test results 4. a negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay 5. a negative test result for covid-2019 by pcr at screening visit 6. no covid-2019 in the medical history 7. no contact with covid-2019 persons within at least 14 days before the enrollment (according to trial subjects) 8. consent to use effective contraception methods during the trial 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. negative drugs or psychostimulants urine test at the screening visit 11. negative alcohol test at the screening visit 12. no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 13. no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.